EGFR and non-small cell lung carcinoma: β‐AR2 was recently demonstrated to cause EGFR TKI resistance through inactivation of LKB1 and induction of interleukin‐6 expression in NSCLC harboring EGFR activating mutation (Nilsson et al., 2017).